NCT03605056 - Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2022

Conditions

Multiple Myeloma

Interventions

DRUG

chidamide

20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle

DRUG

lenalidomide

25 mg/d, will be administered orally on Days 1-14 each 21 day cycle

DRUG

dexamethasone

40mg weekly, will be administered orally or intravenously

Trial Locations (1)

180 Fenglin Road, Shanghai